Ord Minnett Remains a Buy on Telstra Corporation Limited (TTRAF)
Ord Minnett analyst maintained a Buy rating on Telstra Corporation Limited (TTRAF – Research Report) today and set a price target of A$5.00. The company's shares closed last Thursday at $3.15.
Confident Investing Starts Here:
In addition to Ord Minnett, Telstra Corporation Limited also received a Buy from Morgan Stanley's Andrew McLeod in a report issued on May 28. However, on the same day, UBS downgraded Telstra Corporation Limited (Other OTC: TTRAF) to a Hold.
The company has a one-year high of $3.45 and a one-year low of $2.19. Currently, Telstra Corporation Limited has an average volume of 29.92K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TTRAF in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
25 minutes ago
- Hamilton Spectator
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
SAN DIEGO and TORONTO, June 12, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. ('Aptose' or the 'Company') (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today announced data from its Phase 1/2 TUSCANY trial in newly diagnosed AML patients treated with tuspetinib (TUS) in combination with standard of care dosing venetoclax and azacitidine (TUS+VEN+AZA triplet) in an oral presentation at the European Hematology Association Congress (EHA 2025), being held June 12-15, 2025, in Milan, Italy. The TUS+VEN+AZA triplet is being developed as a mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of Medicine, and an investigator in the TUSCANY study, reported safety and efficacy data from the first two dose cohorts at 40 mg of TUS or 80 mg of TUS in the TUS+VEN+AZA triplet. Dr. Mannis also noted three patients were rapidly enrolled on the third dose cohort of 120 mg TUS in the TUS+VEN+AZA triplet, and that no DLTs have been observed to date. The oral presentation at EHA included updated safety, complete remission, minimal residual disease (MRD) assessments, and longer duration of follow-up: Title: TUSCANY Study of Safety and Efficacy of Tuspetinib Plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy Presenter: Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of Medicine Abstract #: S139 Key findings: 'The TUSCANY triplet trial is well under way, and we are observing exciting activity with the addition of TUS to the VEN+AZA standard treatment,' said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. 'The data presented today reveal complete responses across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients. TUS appears to have tremendous opportunity in the largest markets and the most challenging of AML cases.' Abstracts are available on the EHA2025 website here . The presentation is available on the Aptose website here . TUSCANY: TUS+VEN+AZA Triplet Phase 1/2 Study The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 clinical study with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. Earlier APTIVATE trials of TUS as a single agent and in combination as TUS+VEN demonstrated favorable safety and broad activity in diverse relapsed or refractory (R/R) AML populations that went beyond the more prognostically favorable NPM1 and IDH mutant subgroups. Indeed, responses were also in R/R AML patients with highly adverse TP53 and RAS mutations, and those with mutated or unmutated (wildtype) FLT3 genes. The TUSCANY Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS, is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by mid-late 2025. Data will be released as it becomes available. More information on the TUSCANY Phase 1/2 study can be found on ( here ). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit . Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential and safety profile of tuspetinib (including the triplet therapy) and its clinical development, the anticipated enrollment rate in the TUSCANY trial and the timing thereof, as well as statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'should', 'would', 'may', and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences Inc. Susan Pietropaolo Corporate Communications & Investor Relations 201-923-2049 spietropaolo@
Yahoo
an hour ago
- Yahoo
Ivanhoe Mines rating cut after 'materially weaker than anticipated update'
-- Scotiabank analysts downgraded Ivanhoe Mines (OTC:IVPAF) to Sector Perform from Sector Outperform in a note Thursday, following a "materially weaker than anticipated update pertaining to the company's flagship Kamoa-Kakula Cu complex in the DRC." The rating cut is primarily driven by "significant uncertainty on the future operating outlook" after preliminary geotechnical findings indicated that recent seismic activity at Kakula "appears self-induced by mining." While Ivanhoe Mines has implemented a short-term mine plan, it includes "substantially weaker 2025 Cu guidance of 370-420kt (vs. 520-580kt previously and our estimate of 440kt)." More critically, Scotiabank (TSX:BNS) notes that the "medium to long-term mine plan at the complex has been placed under review." Overall, the analysts "anticipate a future revised LOM operating plan (including Kakula) that is still very economic due to grade, but is likely based on lower mining rates, lower reserves, and higher costs." Given the remaining significant uncertainty, Scotiabank has reduced its corporate 10% NAVPS. by "another C$2.02 per share or by 19% based on a materially weaker outlook." Their asset-level Kamoa-Kakula 10% NAVPS declined by 27%. As a result of these revised expectations, Scotiabank has lowered its 12-month target price for Ivanhoe Mines to C$12.00 per share compared to the previous C$16.00 target." The new target is said to be based on "1.4x (vs. 1.5x previously) our 10% NAVPS estimate." Related articles Ivanhoe Mines rating cut after 'materially weaker than anticipated update' Morgan Stanley lifts XPeng target after G7 launch draws early interest Moderna explores outside financing for vaccine trials, shares dip
Yahoo
3 hours ago
- Yahoo
UBS identifies stock winners amid structural growth tailwinds
-- In a note to clients on Thursday, UBS analysts assessed "The Next Big Thing" in global equities, focusing on companies that leverage technology to disrupt various sectors. Through their "Global equity focus list," UBS anticipates "strong structural growth drivers to enable our recommendations to outperform the broader market". The investment theme highlights "greentech, enabling tech, fintech, and healthtech sectors," which UBS views as "leading disruptors in sectors undergoing technological transformation, which should lead to consequential and enduring impact". These stocks are collectively "expected to deliver superior earnings growth to the market, boosted by positive, durable structural trends supporting the theme". In enabling technology, UBS predicts significant growth, with the sector "projected to grow to USD 1.2 trillion by 2025, i.e., 15% CAGR from FY20-25". They "expect investors to benefit from increased tech spending and resulting strong revenue growth for the next few years," with Meta Platforms (NASDAQ:META), Alibaba (NYSE:BABA), Oracle Corporation (NYSE:ORCL), and Microsoft (NASDAQ:MSFT) among the names in its focus list. Greentech is supported by "long-term policy support as major economies work toward reducing carbon emissions and reaching net-zero targets." Rolls-Royce (OTC:RYCEY) is one of the names on the focus list. Fintech fundamentals "remain strong, supported by positive net interest income trends."UBS said Barclays was a top gainer in this area, while Euronext (EPA:ENX) NV is also on the list. While healthtech has seen challenges, UBS sees "significant catch-up potential, and generative A.I. progress should act as another catalyst," noting AstraZeneca (NASDAQ:AZN) as a top gainer. Alcon (NYSE:ALC) and Intuitive Surgical (NASDAQ:ISRG) are other healthtech names featured. Related articles UBS identifies stock winners amid structural growth tailwinds Activist investor Palliser Capital reportedly builds 5% stake in WH Smith Citi highlights sector opportunities based on recent flows
